Gilead Sciences has submitted a new drug application (NDA) to the US Food and Drug Administration (FDA) for an investigational, once-daily single tablet combination regimen to treat HIV-1 infection in adult and pediatric patients 12 years of age and older.
Subscribe to our email newsletter
The tablet combines Gilead’s emtricitabine 200mg and tenofovir alafenamide (TAF) 25mg with Janssen Sciences Ireland’s rilpivirine 25mg (R/F/TAF).
The company said that the data submitted in the NDA support the use of R/F/TAF among patients who are HIV treatment-naïve or who are virologically suppressed and want to replace their current antiretroviral treatment regimen.
Along with the R/F/TAF NDA, a Priority Review voucher acquired from Knight Therapeutics in November 2014 was submitted to the FDA.
The anticipated target action date for the R/F/TAF NDA under the Prescription Drug User Fee Act (PDUFA) is six months after the FDA’s acceptance of the filing.
Gilead Sciences Research and Development executive vice-president and chief scientific officer Norbert Bischofberger said: "R/F/TAF is Gilead’s third TAF-based filing in less than a year, and we are looking forward to the potential to offer people living with HIV another effective treatment option with a favorable safety profile.
"The R/F/TAF filing also represents Gilead’s next collaboration with Janssen in our combined efforts to increase and potentially improve HIV treatments for a range of patients."
TAF is a new, investigational nucleotide reverse transcriptase inhibitor (NRTI) that has shown high antiviral efficacy at a dose less than one-tenth that of Gilead’s Viread (tenofovir disoproxil fumarate, TDF).
Apart from R/F/TAF, two other TAF-based HIV treatments are also under FDA review.
The NDA is based on data from a bioequivalence study which showed that R/F/TAF achieved the same drug levels of emtricitabine and TAF in the blood as E/C/F/TAF (10mg TAF dosage) and the same drug levels of rilpivirine as a 25mg dose of rilpivirine (Edurant) alone.